Friday, August 12, 2022
    HomeHealthHow companies are responding to cancer immunotherapy shortage

    How companies are responding to cancer immunotherapy shortage


    The scarcity of producing slots for CAR-T cells, which has left myeloma sufferers dying on a wait list, got here as a shock to drugmakers and clinicians alike.

    When the Meals and Drug Administration accepted the first myeloma CAR-T product from Bristol Myers Squibb in spring of 2021, there have been already 4 different lymphoma and leukemia CAR-T therapies available on the market. These weren’t going through extreme provide constraints so folks hadn’t anticipated there to be points supplying ide-cel, Bristol’s myeloma CAR-T, stated Yi Lin, the director of the cell remedy program on the Mayo Clinic. However after the approval, the demand rapidly overwhelmed Bristol’s potential to create CAR-T for myeloma — and provide chain points in the course of the pandemic made it tougher to ramp up manufacturing.

    Unlock this text by subscribing to STAT+ and revel in your first 30 days free!


    Source link

    Related articles

    Stay Connected


    Latest posts